Tabula Rasa HealthCare Inc (NASDAQ:TRHC) President Orsula V. Knowlton sold 8,000 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $58.10, for a total value of $464,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
TRHC opened at $64.94 on Friday. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of 191.00 and a beta of 1.66. The company has a current ratio of 0.84, a quick ratio of 0.79 and a debt-to-equity ratio of 0.32. Tabula Rasa HealthCare Inc has a 12-month low of $35.50 and a 12-month high of $91.16.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. M&T Bank Corp acquired a new stake in shares of Tabula Rasa HealthCare during the 4th quarter worth approximately $33,749,000. BlackRock Inc. grew its holdings in shares of Tabula Rasa HealthCare by 1.6% during the 4th quarter. BlackRock Inc. now owns 2,600,884 shares of the company’s stock worth $165,831,000 after purchasing an additional 40,174 shares in the last quarter. Peregrine Capital Management LLC grew its holdings in shares of Tabula Rasa HealthCare by 8.1% during the 4th quarter. Peregrine Capital Management LLC now owns 263,096 shares of the company’s stock worth $16,775,000 after purchasing an additional 19,705 shares in the last quarter. Morgens Waterfall Vintiadis & Co. Inc. grew its holdings in shares of Tabula Rasa HealthCare by 33.3% during the 3rd quarter. Morgens Waterfall Vintiadis & Co. Inc. now owns 16,000 shares of the company’s stock worth $1,299,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Credit Suisse AG grew its holdings in shares of Tabula Rasa HealthCare by 45.1% during the 3rd quarter. Credit Suisse AG now owns 25,998 shares of the company’s stock worth $2,110,000 after purchasing an additional 8,076 shares in the last quarter. 78.00% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have issued reports on the company. Zacks Investment Research raised Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a report on Thursday, December 13th. BidaskClub raised Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a report on Wednesday, November 28th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $80.00 target price on shares of Tabula Rasa HealthCare in a report on Thursday, December 6th. Finally, Benchmark assumed coverage on Tabula Rasa HealthCare in a report on Tuesday, January 8th. They issued a “buy” rating and a $85.00 target price on the stock. Three research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Tabula Rasa HealthCare currently has an average rating of “Buy” and an average target price of $83.48.
WARNING: This article was originally posted by Zolmax and is the sole property of of Zolmax. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://zolmax.com/investing/tabula-rasa-healthcare-inc-trhc-president-sells-464800-00-in-stock/2981940.html.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.
Featured Story: How Do Front-End Loads Impact an Investment?
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.